Adverse effects, pathogenesis and treatment of anti-angiogenetic targeting agents
10.3760/cma.j.issn.1673-422X.2010.03.012
- VernacularTitle:抗肿瘤血管生成靶向药物的不良反应、发生机制及处理
- Author:
Lingling XU
- Publication Type:Journal Article
- Keywords:
Angiogenesis inhibitors;
Neoplasms
- From:
Journal of International Oncology
2010;37(3):196-199
- CountryChina
- Language:Chinese
-
Abstract:
Tumor growth is dependent on angiogenesis.At present,antiangiogenic treatment has been one of the most studied and exploited targets for molecular cancer therapy.Up to date,anti-angiogenesis drugs,which has already been applicated in clinic widely,include bevacizumab,endostar,multi-target tyrosine kinase inhibitor such as sorafenib and sunitinib.The main adverse effects associated with antiangiogenic therapy include hypertension,cardiotoxicity,thrombosis,bleeding,proteinuria,impaired wound healing,gastrointestinal perforation,lassitude,diarrhoea,hand foot shin response,etc,the later three is common in sorafenib and sunitinib.The majority of adverse effects are generally mild to moderate in severity and tolerated by patients.although there are specific,uncommon events that are severe and can be lifethreatening.
